o	Expansion of oncology pipeline with preclinical program aiming to reduce the
burden of colorectal cancer.
o	First-in-class approach building on Nykode's 2nd generation technology and
novel antigen combination.
o	Aim to address distinct patient populations ranging from high-risk
pre-cancerous polyps to colorectal cancer.
o	Executing on the company's strategy to develop a portfolio to reduce cancer at
all stages of cancer development. 

Oslo, Norway, December 14, 2023 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced an expansion of the
pipeline with a potential first-in-class preclinical oncology vaccine program
aimed at preventing and treating colorectal cancer. 

Colorectal cancer begins as a premalignant polyp that grows on the mucosal
surface of the colon or rectum and transforms into malignancy. The disease
development and screening programs represent an opportunity to identify and
treat high-risk patients at early stages in addition to treating patients with
developed malignancies.

Nykode's novel vaccines are based on a careful selection and combination of
highly expressed tumor associated antigens involved in the development and
progression of colonic polyps to colorectal cancer. The program will incorporate
Nykode's 4th module proprietary second-generation technology to further optimize
the immune responses tailored to diverse target populations. The program builds
on Nykode's differentiating competence of creating broad and robust CD8 T cell
responses with the potential to break tolerance against tumor-associated
antigens, as illustrated by data presented at Nykode's recent Capital Market
Day. Strong preclinical data generated in the discovery phase further supports
the induction of potent CD8 T cell responses in both wild-type and HLA
transgenic mice models.

"I am thrilled about this exciting addition to our pipeline, which underscores
Nykode's dedication to creating innovative solutions for an expanding range of
patients in need of alternative therapies," said Mikkel W. Pedersen, Nykode's
Chief Scientific Officer. "Additionally, it signifies our belief in the promise
of cancer vaccines across all stages of cancer development."

"The potential first-in-class program reaffirms Nykode's vision of building a
balanced cancer vaccine portfolio. We are excited about the transformative power
of our next-generation technology with the potential to reduce the burden of
colorectal cancer," commented Michael Engsig, CEO of Nykode. 


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular vaccine technology
specifically targets antigens to antigen presenting cells (APC), which have been
shown to induce a broad, strong and long-lasting antigen specific immune
response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of HPV16 induced malignancies which demonstrated favorable safety and
efficacy results from its Phase 2 trial for the treatment of cervical cancer.
VB10.16 is being expanded into multiple trials for treatment of head and neck
cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen
vaccine, is exclusively out-licensed to Genentech, a member of the Roche Group. 

The Company's partnerships include Genentech within oncology and a multi-target
collaboration with Regeneron in oncology and infectious diseases.
 
Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.


Contact for Nykode Therapeutics ASA:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA 
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway